Your session is about to expire
← Back to Search
CC-99677 for Ankylosing Spondylitis (AS SpA axSpA Trial)
AS SpA axSpA Trial Summary
This trial will study the effects of CC-99677 on patients with Ankylosing Spondylitis over 12 weeks, measuring symptoms, disease activity, quality of life, safety, and tolerability.
- Ankylosing Spondylitis
AS SpA axSpA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAS SpA axSpA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AS SpA axSpA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does CC-99677 have a high potential for patient harm?
"There is some data suggesting that CC-99677 is safe, but none yet to support its efficacy. For this reason, it received a score of 2."
Are there different research facilities testing this medication in our state?
"In total, there are 22 different locations where patients can enroll in this trial. Some notable places include Pioneer Research Solutions in Cypress, Austin Regional Clinic in Austin, and Altoona Center For Clinical Research in Duncansville."
Are there any current openings in this research project for new participants?
"That is correct, the clinical trial listed on clinicaltrials.gov is searching for more participants. The study was first posted on 8/25/2021 and has been updated as recently as 11/17/2022. Right now, 22 locations are enrolling a total of 256 people."
Will this research project be studying individuals who are over 35 years old?
"The age range for patients that are being recruited for this trial are individuals who have not yet reached their 65th birthday but are 18 years old or older."
Who meets the qualifications to participate in this research project?
"This trial is open to 256 patients aged 18-65 who currently have spondylitis or ankylosing. Patients must also meet the following criteria: Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back pain ≥ 4, Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each, Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-fail"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger